Pulmonary Fibrosis Trials
Biorasi Offers International Solutions to Recruitment and Management of Pulmonary Fibrosis Trials
Pulmonary Fibrosis is a rare disease with high morbidity and mortality rates. Clinical trials are commonly focused on the improvement of symptoms, rehabilitation, and the treatment of complications such as lung cancer and pulmonary hypertension. Clinical studies for this pulmonary disease often rely on a global strategy to locate prospective patients, which can lead to challenges related to:
- Expertise in government regulations, such as compliance and good clinical practices (GCP)
- Knowledge of language and cultural diversity differences that will impact the clinical trial
- Drug shipment logistics including import/export policies and customs
Biorasi is a new kind of CRO that conducts multiple global clinical trials each year and is able to support all aspects of study management on an international level.
Biorasi Brings a Global Focus to Pulmonary Fibrosis Studies
As an industry leading CRO with 20 years of experience in providing international project management for clinical trials, Biorasi leverages our knowledge of global studies to ensure compliance and operational efficiency:
- Biorasi is experienced in international trials and can apply that knowledge to ensure clinical site and patient participation for studies in the Americas, Europe, and APAC.
- Our teams of CRAs and Project Managers represent clinical trial experts from cultures all over the world, giving them a better understanding of language and translation requirements, cultural diversity, and current events.
- Additionally, we know the importance of logistics in global clinical trials and develop proactive operational strategies to prepare for any delays in shipping and receiving.
Biorasi also offers decentralized strategies – remote solutions designed to expand the global reach of your clinical trials and accommodate potential patient subjects experiencing travel restrictions.
Connect with us to find the right strategy for your next pulmonary trial. CONTACT US TODAY
